Women’s Interagency HIV Study

Women’s Interagency HIV Study
Name	Women’s Interagency HIV Study
Abbrev	WIHS
Established	1993
Type	Longitudinal cohort study
Location	United States
Focus	Human immunodeficiency virus (HIV)

Women’s Interagency HIV Study is a long-term longitudinal cohort investigation of HIV among women in the United States, designed to characterize clinical, immunologic, behavioral, and social determinants of HIV progression and treatment outcomes. The study informs clinical guidelines, public health programs, and biomedical research through serial clinical assessments, laboratory testing, and epidemiologic analyses. Key outputs have influenced policy debates and clinical standards across federal agencies and academic institutions.

Overview and Objectives

The study aims to evaluate HIV natural history, antiretroviral therapy effectiveness, coinfections, reproductive health, aging, and comorbidities among women, integrating outcomes relevant to obstetrics, infectious disease, oncology, cardiology, and nephrology. Primary objectives include measuring HIV viral dynamics and CD4 trajectories, assessing antiretroviral safety and resistance, and characterizing intersections with hepatitis, human papillomavirus, and tuberculosis outcomes. Secondary objectives emphasize health disparities research involving racial and ethnic minorities and intersections with social services, prisons, and homelessness.

History and Funding

Initiated in 1993 with cooperative agreements led by the National Institute of Allergy and Infectious Diseases, the study expanded under funding from the National Institutes of Health alongside partnerships with the National Institute on Drug Abuse and the Centers for Disease Control and Prevention. Early governance involved academic centers affiliated with Columbia University, Johns Hopkins University, University of California, San Francisco, and Emory University, among others. Over time, federal appropriations and philanthropic contributions supported data harmonization with cohorts such as the Multicenter AIDS Cohort Study and the AIDS Clinical Trials Group.

Study Design and Methodology

WIHS uses prospective cohort methodology with standardized clinical protocols, structured interviews, laboratory assays, biorepositories, and linkages to administrative databases. Core methods include quarterly or semiannual visits for virologic testing, CD4 enumeration, genotypic resistance assays, and gynecologic exams, plus questionnaires on sexual behavior, substance use, and mental health. Advanced methods encompass longitudinal causal inference, marginal structural models, high-throughput sequencing, proteomics, and biomarker validation studies employed in collaboration with academic cores at Harvard, Columbia, and Fred Hutchinson Cancer Research Center.

Participant Recruitment and Demographics

Recruitment targeted diverse urban and regional populations through clinics and community outreach in New York City, San Francisco, Los Angeles, Chicago, Washington, D.C., Atlanta, and Miami. Enrollment included women living with HIV and HIV-seronegative comparison participants, capturing heterogeneity across race and ethnicity with substantial representation from African American, Hispanic/Latina, and Caribbean communities. Age ranges spanned reproductive years into older adulthood, enabling analyses relevant to obstetricians, geriatricians, and primary care providers. Retention strategies leveraged community advisory boards and partnerships with Planned Parenthood and faith-based organizations.

Key Findings and Contributions

The cohort produced seminal findings on antiretroviral therapy impact on maternal morbidity and mortality, interactions between HIV and human papillomavirus leading to cervical neoplasia, and cardiovascular risk profiles among women with HIV. Work from the study clarified effects of protease inhibitors on lipid metabolism, delineated HIV-associated neurocognitive disorders, and documented renal disease patterns prompting revised nephrology screening. WIHS analyses informed oncology risk assessments for Kaposi sarcoma and non-Hodgkin lymphoma and highlighted disparities identified by investigators at Yale, Columbia, and Johns Hopkins that influenced social epidemiology and implementation science.

Impact on Policy and Clinical Practice

Findings contributed to revisions of clinical guidelines from agencies such as the Department of Health and Human Services and influenced screening recommendations by the United States Preventive Services Task Force and advisory committees on maternal health. Evidence from the cohort supported substance use treatment integration into HIV care endorsed by the Substance Abuse and Mental Health Services Administration, and informed vaccine policy deliberations at the Food and Drug Administration and Advisory Committee on Immunization Practices. Data also underpinned modeling used by the Centers for Disease Control and Prevention in surveillance and prevention planning.

Collaborations and Related Studies

The study maintained scientific linkages with the Multicenter AIDS Cohort Study, Women’s Health Initiative, AIDS Clinical Trials Group, MACS/WIHS Combined Cohort Study, and international cohorts in South Africa, Haiti, Brazil, and Peru. Cross-disciplinary collaborations involved investigators from Columbia, UC San Francisco, Emory, University of California Los Angeles, Mount Sinai, and Fred Hutchinson, and partnerships with community organizations such as Black AIDS Institute and Hispanic Health Network. These collaborations facilitated translational research integrating epidemiology, clinical trials, behavioral science, and health services research.

Category:Epidemiological studies Category:HIV/AIDS research